The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial
Letter
[키워드] 1:1
48 hour
48 hours
Activation
Administered
adverse event
African
age
allergy
analyzed
Angola
Antiviral
approved
ARMS
Barcelona
baseline
blinded
block
Cerebrovascular disease
chain
chest X-ray
childbearing
chronic
clinical care
clinical trial
co-morbidity
conducted
contraceptive method
control group
coronary disease
cough
country
COVID-19
COVID-19 disease
COVID-19 patient
criteria
Critical
current
CYP3A4
death
detectable
determine
diagnosed with COVID-19
disease
dissemination
dose
double-blind
drug
early treatment
Efficacy
element
Endemic
EudraCT
excluded
eye
Factor
Fever
flow cytometry
Follow-up visit
Frequency
Gabon
global health
groups
history
home visit
Identified
IgA
IgA level
IgG
IgM
immune response
Immunity
immunology
immunomodulatory
IMPROVE
in vivo
Infection
Inflammatory
inhibitor
interfere
investigator
involved
Isolation
Ivermectin
laboratory parameter
Loa loa
magnitude
marker
median
Nasopharyngeal swab
nasopharyngeal swab PCR
negative
neoplasm
Nigeria
no risk
number
objective
outcome
participant
Patient
Patient care
patients
PCR
PCR cycle
physical
Placebo
placebo group
placebo-controlled
Pneumonia
positive
positive SARS-CoV-2 PCR
post-menopausal
Potential
pregnancy test
pregnant women
progression
proportion
protocol
public health
pulmonary
random
randomised
randomised controlled trial
randomization
randomization list
Randomized
Rapid diagnostic test
reaction
receive
recent
recruited
reduce
Registered
renal
resident
risk
Ritonavir
Safe
Sample size
SARS-CoV-2
SARS-CoV-2 RNA
SARS-CoV-2-specific T cell
secondary
sequence
Seroconversion
severe disease
severity
single center
single dose
Spain
status
Study protocol
subject
submitted
surgical
Symptom
symptom onset
the patient
the SARS-CoV-2
threshold
transcriptomics
Transmission
transmission-blocking
Travel
treated patient
treated patients
Treatment
treatment group
Trial
unblinding
Viral load
virus
vulnerable population
website
with mild disease
women
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter